Drug Profile
Naratuximab emtansine - Debiopharm
Alternative Names: DEBIO 1562; IMGN-529; K7153A-SMCC-DM1Latest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator ImmunoGen
- Class Antineoplastics; Biological toxins; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- No development reported Chronic lymphocytic leukaemia
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 29 Nov 2022 Naratuximab emtansine is still in phase II stage for Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA, Belgium, Bulgaria, Czech Republic, Hungary, Italy, Poland, Switzerland and Ukraine (NCT02564744)
- 11 Dec 2021 Efficacy and adverse events data from a phase II trial in Non-Hodgkin's lymphoma presented at the annual meeting and exposition of the American Society of Hematology (ASH-HEM-2021)